Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dabrafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 20/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 5/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 1.00 |
| ▸ | ERN1 | O75460 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | KRAS | P01116 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
| ▸ | FGR | P09769 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dabrafenib SCHEMBL29350038 | 1.00 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL806377 | 1.00 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL13739419 | 0.99 | BRAF (0.98) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL29352214 | 0.97 | BRAF (0.95) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL1127269 | 0.97 | BRAF (0.95) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL14733912 | 0.95 | BRAF (0.90) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL21425052 | 0.95 | BRAF (0.90) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL2193062 | 0.95 | BRAF (0.90) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL14733909 | 0.94 | BRAF (0.89) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL2191986 | 0.92 | BRAF (0.85) | BRAFNR1I2PLK4EPHB6RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12967 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144794-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCERS | Pattern Computer, Inc. (US) | 2026-05-28 | — | — | US | claimed |
| US-20260146289-A1 | ASSESSING AND TREATING MELANOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2026-05-28 | — | — | US | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-12636376-B2 | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors | IN3BIO LTD. (BM) | 2026-05-26 | — | — | US | claimed |
| WO-2026107416-A1 | SINGLE DOSAGE FORMS CONTAINING ELRAGLUSIB AND AT LEAST ONE OTHER ACTIVE INGREDIENT | ACTUATE THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260139320-A1 | StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine | UNIV OF SOUTH CAROLINA (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| WO-2026102161-A1 | METHODS OF TREATING OVARIAN AND PANCREATIC CANCER | CONCARLO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2022029782-A1 | LONG ACTING ANTICANCER COMPOSITIONS | INTRAGEL THERAPEUTICS LTD. (IL) | 2022-02-10 | — | — | WO | claimed |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-10 | — | — | US | claimed |
| WO-2022026398-A1 | COMBINATION THERAPY FOR CANCER | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-03 | — | — | WO | claimed |
| US-20220031806-A1 | CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEINS FOR TREATING PD-L1 NEGATIVE TUMORS | FIVE PRIME THERAPEUTICS, INC. | 2022-02-03 | — | — | US | claimed |
| EP-3082800-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-02-02 | — | — | EP | claimed |
| CN-108314703-B | Preparation and application of molecular site-specific targeting and activating kinase inhibitor | 亚飞（上海）生物医药科技有限公司 | 2022-02-01 | — | — | CN | claimed |
| US-20220028512-A1 | SMART DOSING FOR CANCER THERAPY | OptimDosing, LLC | 2022-01-27 | — | — | US | claimed |
| WO-2022016844-A1 | INTERFERON-BASED CANCER TREATMENT METHOD AND PHARMACEUTICAL COMPOSITION | 厦门特宝生物工程股份有限公司 | 2022-01-27 | — | — | WO | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |